Quantum BioPharma's Market Manipulation Lawsuit Consolidated; Grant & Eisenhofer Named Lead Counsel
QNTM sits 49% above its 52-week low of $2.07.
Summary
Quantum BioPharma's market manipulation lawsuit against CIBC and RBC has been consolidated with a shareholder class action, and Grant & Eisenhofer has been appointed lead counsel.
Key Events · Legal and Risk Events · QNTM
-
Lawsuit Consolidated
SDNY court consolidated Quantum BioPharma's direct action against CIBC and RBC with a shareholder class action alleging illegal market manipulation.
-
Lead Counsel Appointed
Grant & Eisenhofer P.A., which claims over $30 billion in client recoveries, was appointed lead counsel for the class action.
-
Alleged Manipulation Period
Company's direct action alleges spoofing between January 1, 2020 and August 15, 2024; class action covers shareholders who sold between January 6, 2021 and October 15, 2025.
-
Procedural, Not Merits
The consolidation and lead counsel appointment are procedural developments and do not constitute a determination on the merits or any finding of liability or damages.
Analysis · QNTM · Life Sciences
The SDNY court consolidated Quantum BioPharma's direct action against CIBC and RBC with a shareholder class action, and appointed Grant & Eisenhofer — a firm claiming over $30 billion in recoveries — as lead counsel. This is a procedural step, not a merits ruling, but it materially strengthens the litigation posture by aligning the company's claims with a well-resourced class action. The alleged spoofing period spans January 2020 to August 2024, and the class period extends to October 2025. No damages have been awarded; the outcome remains uncertain.
How filings like this one have moved
In the 30 days to Oct 8, 2026, 28.8% of the 1732 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, QNTM was trading at $3.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $25.4M. The 52-week trading range was $2.07 to $18.13. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.